Zhitai Bio
质肽生物
Zhitai Bio (质肽生物, formally Beijing Zhitai Biomedical Technology) is a Beijing-based biotech company developing peptide therapeutics, founded and led by Zhang Xujia as chairman and CEO . The company has drawn consistent backing from BlueRun Ventures, which led its Series B financing of over RMB 100 million in March 2023 and continued to double down through subsequent rounds . By late 2023, Zhitai had raised nearly RMB 200 million in a Series B+ round led by Meike and the China-US Green Fund, bringing its total fundraising that year to nearly RMB 300 million . BlueRun Ventures positions Zhitai among its portfolio of differentiated, internationally-oriented biotech bets in the peptide drug space, alongside companies like Nankai Hecheng and Zhuanyan Bio .
AI-generated — may contain errors, please verify.
Coverage
After Breaking Ground, Growth Follows | Quarterly
The stage is set. Your entrance awaits.
5Y News | QLT Biotherapeutics Raises Over 500 Million RMB in Series C Funding
Zhitai Biotech Closes Over 500 Million Yuan Series C Round to Accelerate Core Clinical Pipeline Development
BlueRun Ventures Continues to Double Down as QLT Biotherapeutics Closes Over RMB 500 Million Series C Round | BlueRun Family
Accelerate core clinical pipeline development
BlueRun Ventures in Conversation with QUA Biotech, AllinkBio, and Zenitar: Breaking Out of the Red Sea — The "Value" Evolution of China's Innovative Drugs
The Leap from "Imitation and Followership" to "Original Innovation"
Dawn Breaks, Toward the Light | BlueRun Ventures 2025 Annual Fund Partners Meeting
Welcoming the Dawn of Technology
Planting Spring in the Wind | Quarterly
On the Move
The Power of Waiting to Grow in the Snow | BlueRun Ventures Bi-Monthly Report
"Clear skies after a flurry of snow"
Beyond the Quadrant: Forging an Undefined Path | BlueRun Ventures 2024 Annual Fund Partners Meeting
Breaking Through a Mental Block
A New Drug King Is About to Be Crowned. Does Peptide Still Have Its Next Billion-Dollar Target? | BlueRun Ventures Viewpoint
You can only find things when you're not looking for them.
Breaking Through Your Mental Block in an Olympic Year | BlueRun Ventures Bi-Monthly Report
OUVRONS GRAND LES JEUX This text is already in French, not Chinese. It translates to English as: **LET THE GAMES BEGIN** Or more literally: "Let's open the games wide" / "Let the games open grandly" (This is the official slogan/tagline for the Paris 2024 Olympic and Paralympic Games.)
Zhitai Bio's GLP-1 Product Semaglutide Injection Licensed to Tonghua Dongbao | BlueRun Ventures Headlines
It has the potential to become one of the first semaglutide biosimilars to be approved and commercially launched in China.
The Trillion-Yuan Blueprint for Peptide Drugs: From Diabetes Medication to Weight-Loss Wonder | BlueRun Ventures Biotech Forum Recap
From Pharmaceuticals to Consumer Goods: A Wave of Value Creation
The Future Looks Very Different | December & January Bimonthly Report
Witnessing BlueRun Ventures' "Defining Moment"
BlueRun Ventures Quarterly Investment & Financing Overview | 2023 Q4
Sector distribution spans artificial intelligence, enterprise services, hard tech, and biotech, among others.
BlueRun Ventures and Its Portfolio Companies Win Multiple Awards from Forbes China, TMTpost, Jiemian News, and Cyzone
Standing alongside founders from zero to one to redefine the future.
Looking at the Other Side of the Coin | October & November Report
Grateful for what life has given
BlueRun Ventures | BlueRun Ventures Continues to Double Down, Zhitai Bio Closes Nearly RMB 200 Million Series B+ Round
Focused on developing recombinant protein therapeutics using an *E. coli*-based technology platform.
A Pill's Journey from Lab to Industry | BlueRun Ventures Biotech Salon Series
The investment logic in biotech has quietly shifted.
BlueRun Ventures Quarterly Investment Roundup | 2023 Q1
The fund's sector distribution spans artificial intelligence, enterprise services, hard tech, and biotech.
Official Announcement: BlueRun Ventures Has Hired Virtual Knowledge Workers | March Report
Midjourney designers, your hard work is appreciated.
BlueRun Ventures Leads Series B Financing Round of Over 100 Million RMB for QLT Biotechnology | BlueRun Ventures Portfolio
It is poised to become one of the key players in the metabolic disease space, both domestically and globally.
